Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 2009

View Archived Issues

DSMB recommends continuation of Stem Cell Therapeutics' phase IIb stroke trial of NTx-265

Cara Therapeutics describes novel CB2 receptor agonists for the treatment of pain

Genentech and Array BioPharma present Raf kinase inhibitors for cancer treatment

Nurr-1 receptor ligands disclosed by sanofi-aventis for the treatment of epilepsy

Novel histamine H3 receptor antagonists in development at Evotec Neurosciences

Novartis describes CXCR2 receptor antagonists for the treatment of COPD

Merck & Co. claims novel hypoxia-inducible factor prolyl hydroxylase inhibitors

CAL-120, with potent in vivo antitumor activity, selected for clinical evaluation

Once-daily mesalazine is as effective as twice-daily dosing in UC remission maintenance

Ondansetron confers no significant improvement in emesis in children with acute gastroenteritis

Promising phase II data on AZD-0837 support further evaluation in AF patients

Lundbeck reports results from third quarter of 2009

GW Pharmaceuticals completes recruitment in phase II/III trial of Sativex in cancer pain

EMEA grants orphan drug status to LFB Biotechnologies' LFB-R603 antibody for CLL

Novartis and Incyte sign exclusive license agreement for INCB-18424 and INCB-28060

AEterna reports results of phase II trial of AEZS-108 in endometrial cancer

Biovitrum completes phase II clinical study of Kiobrina in preterm infants

Aflibercept shows promise in phase II trial in metastatic melanoma patients

Ohr presents update on clinical development of OHR/AVR-118 for cachexia

Genfit reports results from phase II trial of GFT-505 in fatty liver diseases

IWT awards grant to Ablynx for development of Nanobodies

DNDi receives grant from Bill and Melinda Gates Foundation to develop fexinidazole for HAT

Cleveland BioLabs initiates enrollment in safety study of CBLB-502 for ARS

University of Minnesota and Celladon develop technology for screening drugs in heart failure

FDA grants traditional approval to Tibotec's NNRTI drug Intelence

Merck & Co. to initiate phase IIa clinical trial of MK-6913 for vasomotor symptoms

University of Navarra initiates clinical trial of personalized vaccines for glioblastoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...